glp-1 user Users: Who They Are, What They Eat, How They Live Circana highlights role of personalization

Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and a nested case-control study (Bezin et al., 2023) that reported increased risk for thyroid cancer following GLP-1 RA-based interventions

That raises the prospect, she said, that patients will stop taking the drugs and regain weight, which will lead to poor clinical outcomes. Join our commenting forum Join thought-provoking conversations, follow other Independent readers and see their replies Comments

This happens because your body is adjusting to a higher amount of medication, and symptoms often improve with time

But beneath the buzz lies a fascinating piece of biology